Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Date:6/8/2008

the trial is expected to take approximately fourteen months: two months for screening, three months for subject treatment and a further nine months for subject follow-up. Individuals interested in participating in this trial should visit http://www.clinicaltrials.gov/ .

Phase 2 Study of SB-509 to Evaluate Stem Cell Mobilization (SB-509-703)

Twenty subjects will be enrolled in the stem cell mobilization Phase 2 trial. Subjects will be randomized to one of four cohorts with 5 subjects in each cohort. Cohorts 1 and 2 will receive a single treatment of 30 mg into one leg or 60 mg (30 mg in each leg) of SB-509, respectively, by intramuscular (IM) injection on Day 0. Cohort 3 will receive a single treatment of an equal volume of placebo by IM injection into a lower limb on Day 0. Cohort 4 will receive two treatments of 60 mg of SB-509 (30 mg in each leg) by IM injection (Day 0 and 90). Subjects will receive injections in a distribution pattern that targets the major peripheral nerves in the legs and feet.

Peripheral blood samples taken before and at various times post-treatment with SB-509 will be assayed and the numbers of circulating stem cells will be assessed using stem cell-specific enzymatic activity (aldehyde dehydrogenase staining), culture-based assays, as well as assays of cell surface expression of stem cell-specific markers.

The signs and symptoms of diabetic peripheral neuropathy and any changes that occur during the trial will also be evaluated based on neurological examination data (NIS-LL), electrophysiological testing data, subject neurological questionnaire, and subject pain assessment (VASPI). Specifically, investigators will use the following tests: QST with the Vibratron II instrument, to assess the threshold of detection of vibration and electrophysiological testing. A total neuropathy composite score (TNS) will also be computed to evaluate changes in nerve health.
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
2. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
3. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
6. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
7. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
8. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
9. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
10. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... CHESTERBROOK, Pa., Oct. 30, 2014   Auxilium ... a fully integrated specialty biopharmaceutical company, today announced ... 30, 2014. The Company highlighted important corporate, commercial, ... "We are very pleased with ... core growth products in our portfolio this quarter, ...
(Date:10/30/2014)... 2014 , Extensively hydrolyzed milk ...   Cow milk protein allergy (CMPA) is the leading cause ... now, it has been managed by eliminating milk proteins ... that it is possible to help build of oral ... children during the first year of life by using ...
(Date:10/30/2014)... 2014 nebulizer is a medical device used ... cystic fibrosis) that converts liquid medication into mist or ... lungs of a patient when inhaled through the mouth ... dominated by various devices powered by electric current and ... COPD and cystic fibrosis and growing number of geriatric ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 3Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 4Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 5Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 6Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 7Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 8Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 9Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 10Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 11Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 12Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 13Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 14Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 15Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 16Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 17Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 18Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 19Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 20Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 21Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 22Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3
... 12, 2007 /PRNewswire-FirstCall/ --,InB:Biotechnologies, Inc. ("BioTech"), a ... announced strong positive,results in studies of vaccines ... novel, proprietary AIPwLV(TM) vaccine technology. The,studies were ... Molecular,Biotechnology (CMB), the Contract Research Organization led ...
... LUND, Sweden, March 13, 2007--Active Biotech AB,(Stockholm:ACTI.ST) ... a first human micro-dosing trial of an,I-3D ... was to determine the pharmacokinetic,characteristics of the ... healthy volunteers. , The study demonstrated that ...
Cached Medicine Technology:Integrated Biopharma's Proprietary Vaccine Technology Achieves,Strong Positive Results 2Active Biotech's I-3D Micro-dosing Clinical Trial Concluded 2
(Date:10/30/2014)... FL (PRWEB) October 30, 2014 ... Joint Commission Accredited teleradiology and specialty telemedicine solutions ... in addition to its existing teleradiology services at ... second opinion and expert telemedicine services, to the ... , As a result of this innovative partnership, ...
(Date:10/30/2014)... The human brain is often overlooked ... to help maintain better mental health, according to Dr. ... Lose Your Memory in 100 Ways’ for just that ... conflicting attitudes to help keep the reader constantly thinking. ... must decipher the hidden logic within. , “If you ...
(Date:10/30/2014)... 2014 Victory Healthcare, a privately ... third quarter infection rates and patient satisfaction scores. ... of only two percent or less, and the ... 98 percent. , “We are delighted with our ... satisfaction scores,” said Robert Helms, chairman and CEO ...
(Date:10/30/2014)... (HealthDay News) -- When it comes to heart disease, a ... delay care when they have symptoms that spell trouble. ... hospital with a more severe or advanced stage of heart ... Catherine Kreatsoulas, a Fulbright Scholar and research fellow at the ... from the Heart and Stroke Foundation of Canada. In ...
(Date:10/30/2014)... Amy Norton HealthDay Reporter ... to a common plastics, chemical during pregnancy may have effects ... Researchers found that baby boys born to moms with ... a shorter anogenital distance -- the space between the genitals ... it,s considered a marker of exposure to androgens ("male" hormones) ...
Breaking Medicine News(10 mins):Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Women Often Ignore Signs of Heart Trouble 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3
... San Francisco, Calif., June 07, 2008 Results ... were announced today at the American Diabetes Association ... & Development Center, Inc. Alogliptin, which has ... of dipeptidyl peptidase-4 (DPP-4), is currently under investigation ...
... of,Labor & Industry invites the public to learn more about ... Safety Day from 10 a.m. to 2,p.m. on Wednesday, June ... event will feature an array of interactive services promoting,health and ... can,receive - free of charge - relaxing massages; a cool ...
... they had dropped off at wheel, with 2.2% reporting accidents ... while suffering from a lack of sleep may be a ... , Interviews with 263 students at the University of North ... driving, and 2.2 percent of that group reported having accidents ...
... Physicians (ACP) today pledged its support for enactment of ... Providers Act of 2008. , "The College is able ... incorporates three of our top legislative priorities," ACP President ... (D-MT), chairman of the Senate Finance Committee. , Writing ...
... the nation,s leading,supplier of replacement medical repair parts ... Edge" award for Northern Ohio. The,Entrepreneurs EDGE is ... companies in Northeast Ohio grow their value, while,building ... The,Leading EDGE Award measures, tracks and recognizes companies ...
... AJMC, findings reveal only a handful of measures ... inform health care payers,purchasers, providers and policy makers ... collection methods for physician quality measurement,efforts, Bridges to ... financial impact that results when physicians meet certain ...
Cached Medicine News:Health News:Phase 3 results for alogliptin 2Health News:Phase 3 results for alogliptin 3Health News:Sleepy Driving Prevalent Among Collegians 2Health News:ACP pledges support for Medicare improvements for Patients and Providers Act of 2008 2Health News:Bridges to Excellence Study Assesses Clinical and Financial Impact of Physician Quality Measures 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: